Globus Medical (GMED) Q3 2026 Earnings Call Transcript
Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, down 0.7% YoY. Non-GAAP EPS was $1.23, up 4%. Free cash flow hit a record $225M. U.S. Spine grew 2%, while Nevro declined 26%. The company expects growth from new product launches in 2027, including SCRIPT implants and EIQ suite. Trauma business grew 19%.
How this was made
The 30-second read
Why it matters
The earnings release offers fresh guidance and cash metrics, informing short‑term trading decisions and longer‑term positioning on the company's growth trajectory.
Market read
First disclosure of Q3 2026 results; provides new data for traders evaluating the stock.
What to watch
Delayed product launches and Nevro rightsizing may suppress near‑term growth, but long‑term upside from SCRIPT and EIQ lines remains significant.
Background
Globus Medical provided detailed segment performance, highlighted new product launches (SCRIPT, XLIF Prone Solution) and updates on FDA warning‑letter closure.
Ticker impact
Q3 2026 earnings call disclosed revenue of $763.7M, non‑GAAP EPS $1.23 and a $225M free cash flow record.
potential modest move as investors weigh revenue decline against strong cash flow and buyback activity
Revenue fell 0.7% while EPS rose 4%; record free cash flow and share repurchase suggest support, but declining base revenue may limit upside.
Market effects
Spine and medical device sector may see scrutiny on growth rates and product launch timelines.
U.S. healthcare equities could experience slight volatility following the earnings release.
Limited; impact confined to medical‑device investors and related supply‑chain participants.
Counterpoint
Despite revenue dip, the strong cash position and ongoing product pipeline could support a rally.
Key entities
- companyGlobus Medical
Medical device manufacturer specializing in spine and trauma solutions.
